Tight junction formation in epithelial ovarian adenocarcinoma

References

• Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl. 1995; 23: 208–18
   PubMedGoogle Scholar
• Blaustein A. Surface (germinal) epithelium and related ovarian neoplasms. Pathol Annu. 1981; 16 Pt 1: 247–94
   PubMedGoogle Scholar
• Blaustein A, Kaganowicz A, Wells J. Tumor markers in inclusion cysts of the ovary. Cancer 1982; 49: 722–6
   PubMed Web of Science ®Google Scholar
• Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer. 1994; 73: 1859–64
   PubMed Web of Science ®Google Scholar
• Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Proc Natl Acad Sci USA. 1999; 96: 10501–6
   PubMed Web of Science ®Google Scholar
• Johnson LG. Applications of imaging techniques to studies of epithelial tight junctions. Adv Drug Deliv Rev. 2005; 57: 111–21
   PubMed Web of Science ®Google Scholar
• Mullin JM. Potential interplay between luminal growth factors and increased tight junction permeability in epithelial carcinogenesis. J Exp Zool. 1997; 279: 484–9
   PubMedGoogle Scholar
• Tsukita S, Furuse M. The structure and function of claudins, cell adhesion molecules at tight junctions. Ann N Y Acad Sci. 2000; 915: 129–35
   PubMed Web of Science ®Google Scholar
• Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol. 2003; 19: 207–35
   PubMed Web of Science ®Google Scholar
• Rask K, Nilsson A, Brannstrom M, Carlsson P, Hellberg P, Janson PO, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer. 2003; 89: 1298–304
   PubMed Web of Science ®Google Scholar
• Zhu Y, Maric J, Nilsson M, Brannstrom M, Janson PO, Sundfeldt K. Formation and barrier function of tight junctions in human ovarian surface epithelium. Biol Reprod. 2004; 71: 53–9
   PubMed Web of Science ®Google Scholar
• Zhu Y, Brannstrom M, Janson PO, Sundfeldt K. Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer. 2006; 118: 1884–91
   PubMed Web of Science ®Google Scholar
• Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer. 1997; 74: 275–80
   PubMed Web of Science ®Google Scholar
• Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol. 1997; 28: 922–8
   PubMed Web of Science ®Google Scholar
• Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology. 1998; 32: 69–80
   PubMed Web of Science ®Google Scholar
• Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR, Jr, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol. 2004; 165: 397–414
   PubMed Web of Science ®Google Scholar
• Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000; 60: 6281–7
   PubMed Web of Science ®Google Scholar
• Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alo PL, Lancaster WD, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003; 9: 2567–75
   PubMed Web of Science ®Google Scholar
• Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004; 112: 14–25
   PubMed Web of Science ®Google Scholar
• Agarwal R, D'Souza T, Morin PJ. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005; 65: 7378–85
   PubMed Web of Science ®Google Scholar
• Matter K, Balda MS. Functional analysis of tight junctions. Methods. 2003; 30: 228–34
   PubMed Web of Science ®Google Scholar
• Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001; 22: 255–88
   PubMed Web of Science ®Google Scholar
• Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest. 1994; 71: 510–8
   PubMed Web of Science ®Google Scholar
• Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?. Gynecol Oncol. 1999; 72: 437–42
   PubMed Web of Science ®Google Scholar
• Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res. 2004; 10: 4427–36
   PubMed Web of Science ®Google Scholar
• Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004; 10: 3291–300
   PubMed Web of Science ®Google Scholar
• Ivarsson K, Runesson E, Sundfeldt K, Haeger M, Hedin L, Janson PO, et al. The chemotactic cytokine interleukin-8 – a cyst fluid marker for malignant epithelial ovarian cancer?. Gynecol Oncol. 1998; 71: 420–3
   PubMed Web of Science ®Google Scholar
• Sundfeldt K, Ivarsson K, Rask K, Haeger M, Hedin L, Brannstrom M. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts. Anticancer Res. 2001; 21: 65–70
   PubMed Web of Science ®Google Scholar
• Mullin JM, Agostino N, Rendon-Huerta E, Thornton JJ. Keynote review: epithelial and endothelial barriers in human disease. Drug Discov Today. 2005; 10: 395–408
   PubMed Web of Science ®Google Scholar
• Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol. 2002; 156: 1099–111
   PubMed Web of Science ®Google Scholar
• Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006; 6: 186
   PubMed Web of Science ®Google Scholar
• Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest. 2005; 115: 1765–76
   PubMed Web of Science ®Google Scholar
• Lee JW, Lee SJ, Seo J, Song SY, Ahn G, Park CS, et al. Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecol Oncol. 2005; 97: 53–9
   PubMed Web of Science ®Google Scholar
• Furuse M, Furuse K, Sasaki H, Tsukita S. Conversion of Zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin–Darby canine kidney I cells. J Cell Biol. 2001; 153: 263–72
   PubMed Web of Science ®Google Scholar
• Turksen K, Troy TC. Permeability barrier dysfunction in transgenic mice overexpressing claudin 6. Development. 2002; 129: 1775–84
   PubMed Web of Science ®Google Scholar
• Dunfield LD, Shepherd TG, Nachtigal MW. Primary culture and mRNA analysis of human ovarian cells. Biol Proc Online. 2002; 4: 55–61
   PubMedGoogle Scholar
• Bayani J, Brenton JD, Macgregor PF, Beheshti B, Albert M, Nallainathan D, et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res. 2002; 62: 3466–76
   PubMed Web of Science ®Google Scholar
• Israeli O, Gotlieb WH, Friedman E, Korach J, Friedman E, Goldman B, et al. Genomic analyses of primary and metastatic serous epithelial ovarian cancer. Cancer Genet Cytogenet. 2004; 154: 16–21
   PubMedGoogle Scholar
• McClane BA. Clostridium perfringens enterotoxin acts by producing small molecule permeability alterations in plasma membranes. Toxicology. 1994; 87: 43–67
   PubMed Web of Science ®Google Scholar
• Santin AD, Cane S, Bellone S, Palmieri M, Siegel ER, Thomas M, et al. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res. 2005; 65: 4334–42
   PubMed Web of Science ®Google Scholar